Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases

医学 恶心 呕吐 耐受性 皮疹 替莫唑胺 内科学 达卡巴嗪 抗坏血酸 胃肠病学 化疗 不利影响 外科 麻醉 食品科学 化学
作者
Timothy E. Bael,Bercedis L. Peterson,Jared Gollob
出处
期刊:Melanoma Research [Lippincott Williams & Wilkins]
卷期号:18 (2): 147-151 被引量:55
标识
DOI:10.1097/cmr.0b013e3282f2a7ae
摘要

We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma. Planned enrollment was for 40 patients. Eligible patients were required to have metastatic melanoma with or without brain metastases, an ECOG performance status of 0-2, and adequate organ function. The primary endpoints were overall response rate and degree of grade 4 toxicity. ATO was administered as a loading dose at 0.25 mg/kg/day for 5 days during week 0, and then twice weekly at 0.35 mg/kg during an 8-week cycle. Each infusion of ATO was followed by an infusion of 1000 mg of AA. TMZ was given at the standard dose of 200 mg/m for 5 days during weeks 1 and 5 of each cycle. Eleven patients were enrolled with 10 evaluable for response, five with central nervous system disease. No responses were seen among the first 10 patients and on the basis of a predetermined stopping rule, the trial was terminated. Common grade 1 and 2 side effects included nausea and vomiting (10), fatigue (six), edema (six), rash (six), and elevated AST or ALT (six). Grade 3 and 4 side effects included nausea and vomiting (three), elevated AST or ALT (two), seizure (one), and renal failure (one). This is the first trial combining ATO with chemotherapy in a solid tumor. ATO and AA were administered in the outpatient setting with TMZ in 11 patients with an acceptable side effect profile. No responses were seen in the first 10 evaluable patients leading to early closure of the study. Further studies using ATO and AA with TMZ with this dosing schedule in advanced melanoma are not warranted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
桐桐的应助被eh采纳,获得10
2秒前
2秒前
2秒前
陈皮泡泡糖完成签到,获得积分10
2秒前
八木发布了新的文献求助10
2秒前
小酒窝完成签到 ,获得积分10
3秒前
Hu完成签到,获得积分10
3秒前
4秒前
fan发布了新的文献求助10
4秒前
共享精神的应助被xiaogua采纳,获得10
4秒前
5秒前
香蕉觅云的应助被白青采纳,获得10
5秒前
5秒前
6秒前
思源的应助被叶子采纳,获得10
6秒前
houzhi6678完成签到,获得积分10
6秒前
爆米花的应助被MaximWang采纳,获得10
6秒前
天天快乐的应助被ai采纳,获得10
6秒前
samo发布了新的文献求助10
7秒前
王苏仑完成签到,获得积分10
7秒前
爆米花的应助被科研通管家采纳,获得10
7秒前
7秒前
SciGPT的应助被小明同学采纳,获得10
7秒前
shen的应助被科研通管家采纳,获得20
8秒前
打打的应助被科研通管家采纳,获得10
8秒前
8秒前
ding的应助被科研通管家采纳,获得10
8秒前
8秒前
cz完成签到,获得积分10
8秒前
Akim的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
丘比特的应助被科研通管家采纳,获得20
8秒前
NexusExplorer的应助被无私愚志采纳,获得10
8秒前
李健的小迷弟的应助被leajay采纳,获得10
8秒前
顾矜的应助被科研通管家采纳,获得10
8秒前
9秒前
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163835
求助须知:如何正确求助?哪些是违规求助? 9557925
关于积分的说明 21742693
捐赠科研通 7754454
什么是DOI,文献DOI怎么找? 3428350
关于科研通互助平台的介绍 2553034
邀请新用户注册赠送积分活动 2472982